- Simply Wall St. via Yahoo FinanceSep 04 14:55 PM
Mihael Polymeropoulos has been the CEO of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) since 2003. This analysis aims first to contrast CEO compensation with other companies ...
Vanda Pharmaceuticals Applauds the EPA's Landmark Commitment to Eliminate Animal Testing and Urges the Food and Drug Administration...Market Watch6 days ago
Insomnia Treatment Market - Global Industry Analysis, Size, Share, Trends, Segmentation and Forecast 2019 - 2025Market Watch3 days ago
Insomnia Market 2019 Share, Size - Global Industry Insights by Supply Demand and Shortage, Outlook, Forecast to 2028Market Watch3 hours ago
- Benzinga via Yahoo FinanceAug 28 12:02 PM
PDUFA dates are deadlines for the FDA to review new drugs. The FDA is normally given 10 months to review new drugs. If a drug is selected for priority review, the FDA is allotted six months to review the drug.
- related to Vanda Pharmaceuticals Inc